Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28786452 | 0.89 | CYP4F2 (0.42) | CYP19A1AKR1B1LMNAGRIN2DGRIN3B | |
| SCHEMBL28168240 | 0.84 | APEX1 (0.44) | CYP19A1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27643038 | 0.84 | TNKS2 (0.49) | CYP19A1AKR1B1NPC1MAPTRAB9A | |
| SCHEMBL16244900 | 0.83 | TAAR1 (0.58) | — | |
| SCHEMBL14783546 | 0.82 | SMN1; SMN2 (0.60) | LMNANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL112110 | 0.81 | KMT2A (0.44) | CYP19A1GRIN2DGRIN3BGRIN1GRIN2A | |
| Carbamic Acid SCHEMBL27856575 | 0.79 | L3MBTL1 (0.43) | CYP19A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14672756 | 0.76 | MTNR1A (0.49) | CYP19A1AKR1B1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL28003037 | 0.76 | ATM (0.59) | CYP19A1ALDH1A1KMT2A | |
| SCHEMBL16453478 | 0.74 | CYP19A1 (0.53) | CYP19A1AKR1B1CALM1DAOPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724418-A1 | TRICINE AND CITRIC ACID-BASED CATIONIC LIPIDS | Sanofi (FR) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025104706-A2 | SMALL MOLECULE MODULATORS OF MAS AND MRGD RECEPTORS | XITRA THERAPEUTICS GMBH (DE) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554671-A1 | CYCLIC PEPTIDE INHIBITORS OF IL-23 | JANSSEN Pharmaceutica NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025003759-A1 | DIANHYDROHEXITOL BASED IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | SANOFI (FR) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025003755-A1 | HELPER LIPIDS FOR NUCLEIC ACID DELIVERY | SANOFI (FR) | 2025-01-02 | — | — | WO | disclosed |
| EP-4337665-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024015958-A1 | CYCLIC PEPTIDE INHIBITORS OF IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | WO | disclosed |
| EP-4217340-A1 | TES-BASED CATIONIC LIPIDS | Translate Bio, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4126813-A1 | PHENOLIC ACID LIPID BASED CATIONIC LIPIDS | Translate Bio, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022240978-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022066678-A1 | TES-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-2598170-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015681-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |